Study Finds ctDNA Testing For Minimal Residual Disease Can Cut Costs By 21% For Health Plans When Used For Stage II Colorectal Cancer Treatment Decisions
Portfolio Pulse from Benzinga Newsdesk
A recent study has found that using ctDNA testing for minimal residual disease in Stage II colorectal cancer treatment decisions can reduce costs for health plans by 21%.
May 31, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Quest Diagnostics (DGX) could benefit from the study showing that ctDNA testing for minimal residual disease in Stage II colorectal cancer can reduce health plan costs by 21%.
Quest Diagnostics is a major provider of diagnostic testing services, including ctDNA testing. The study's findings could lead to increased adoption of ctDNA testing, benefiting DGX's revenues.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80